RDY
Dr. Reddy's Laboratories is an integrated global pharmaceutical company operating through three segments: Global Generics, which manufactures and markets branded and generic finished pharmaceuticals including biosimilars and consumer healthcare products; Pharmaceutical Services and Active Ingredients, which produces active pharmaceutical ingredients and provides contract research services; and Others, which includes Aurigene Oncology Limited, a biotechnology subsidiary engaged in discovery and early clinical development of small molecule oncology and inflammation therapies, along with a proprietary products business focused on differentiated formulations. The company's innovation pipeline includes new chemical entities, new biological entities, cell and gene therapy, and digital therapeutics aimed at addressing unmet patient needs across its key markets in the United States, India, Russia, and Europe.